细胞治疗市场规模、份额及成长分析（按技术、类型、细胞类型、细胞来源、应用、最终用户和地区）—2025 年至 2032 年产业预测

2023 年细胞治疗市场规模价值 69 亿美元，预计将从 2024 年的 83.8 亿美元成长到 2032 年的 398.1 亿美元，预测期间（2025-2032 年）的复合年增长率为 21.5%。

全球细胞治疗市场正在经历显着增长，主要原因是退化性疾病和慢性疾病的日益流行，这些疾病需要创新的治疗方法。干细胞研究和再生医学的进步正在扩大治疗前景并为疾病管理提供新的途径。对细胞研究的大量投资进一步推动了新型治疗方法的发展，为行业相关人员创造了丰厚的利润机会。个人化医疗的需求不断增长，即根据患者的个人情况量身定制治疗方案，这也促进了人们对细胞疗法的兴趣日益浓厚。然而，一些挑战可能会阻碍市场成长。开发和生产细胞疗法的成本高昂，令人难以承受，尤其是对于较小的製药公司和研究机构。此外，免疫排斥的风险仍然令人担忧，需要严格的测试和检验以确保患者的安全。复杂而严格的监管核准流程进一步延迟了新治疗方法的商业化，并对市场进入构成了障碍。儘管面临这些挑战，但在持续研究、技术进步以及对慢性和退化性疾病有效治疗的迫切需求的推动下，细胞治疗市场预计在未来几年将大幅扩张。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析

细胞治疗市场规模：依技术及复合年增长率（2025-2032）

• 市场概览
• 体细胞技术
• 细胞永生化技术
• 病毒载体技术
• 基因组编辑技术
• 细胞可塑性技术
• 3D技术

细胞治疗市场规模（按类型及复合年增长率） (2025-2032)

• 市场概览
• 自体移植
• 同种异体

细胞治疗市场规模（按细胞类型和复合年增长率） (2025-2032)

• 市场概览
• 干细胞
• 非干细胞

细胞治疗市场规模：依细胞来源及复合年增长率（2025-2032）

• 市场概览
• iPSCs
• 骨髓
• 脐带血衍生细胞
• 脂肪组织
• 神经干细胞

细胞治疗市场规模：按应用和复合年增长率（2025-2032）

• 市场概览
• 肌肉骨骼
• 心血管
• 胃肠道
• 神经系统
• 肿瘤学
• 皮肤科
• 伤口和损伤
• 眼科
• 其他的

细胞治疗市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概览
• 医院和诊所
• 再生医学中心
• 诊断与研究中心
• 其他的

细胞治疗市场规模：按地区和复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Novartis AG（Switzerland）
• Gilead Sciences, Inc.（USA）
• Bristol Myers Squibb（USA）
• Johnson & Johnson（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Bluebird Bio, Inc.（USA）
• Mesoblast Limited（Australia）
• CRISPR Therapeutics（Switzerland）
• Adaptimmune Therapeutics plc（UK）
• Fate Therapeutics, Inc.（USA）
• Orchard Therapeutics plc（UK）
• Gamida Cell Ltd.（Israel）
• Allogene Therapeutics, Inc.（USA）
• Capricor Therapeutics, Inc.（USA）
• Vericel Corporation（USA）
• Mustang Bio, Inc.（USA）
• Atara Biotherapeutics, Inc.（USA）

结论和建议

Cell Therapy Market size was valued at USD 6.9 Billion in 2023 and is poised to grow from USD 8.38 Billion in 2024 to USD 39.81 Billion by 2032, growing at a CAGR of 21.5% during the forecast period (2025-2032).

The global cell therapy market is experiencing significant growth, primarily driven by the increasing prevalence of degenerative disorders and chronic diseases, which necessitate innovative treatment approaches. Advancements in stem cell research and regenerative medicine are expanding the therapeutic landscape, offering new avenues for disease management. Substantial investments in cell research are further propelling the development of novel therapies, creating lucrative opportunities for industry stakeholders. The rising demand for personalized medicine, which tailors treatments to individual patient profiles, is also contributing to the heightened interest in cell-based therapies. However, several challenges may impede market growth. The high costs associated with the development and manufacturing of cell therapies can be prohibitive, particularly for smaller pharmaceutical companies and research institutions. Additionally, the risk of immune rejection remains a concern, necessitating rigorous testing and validation to ensure patient safety. Complex and stringent regulatory approval processes can further delay the commercialization of new therapies, posing hurdles for market entrants. Despite these challenges, the cell therapy market is projected to expand significantly in the coming years, driven by continuous research, technological advancements, and the pressing need for effective treatments for chronic and degenerative diseases.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cell Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cell Therapy Market Segments Analysis

Global Cell Therapy Market is segmented by Technology, Type, Cell Type, Cell Source, Application, End-User and region. Based on Technology, the market is segmented into Somatic Cell Technology, Cell Immortalization Technology, Viral Vector Technology, Genome Editing Technology, Cell Plasticity Technology and Three-Dimensional Technology. Based on Type, the market is segmented into Autologous and Allogeneic. Based on Cell Type, the market is segmented into Stem Cell and Non-Stem Cell. Based on Cell Source, the market is segmented into iPSCs, Bone Marrow, Umbilical Cord Blood-Derived Cells, Adipose Tissues and Neural Stem Cell. Based on Application, the market is segmented into Musculoskeletal, Cardiovascular, Gastrointestinal, Neurological, Oncology, Dermatology, Wounds and Injuries, Ocular and Others. Based on End-User, the market is segmented into Hospitals and Clinics, Regenerative Medicine Centres, Diagnostic and Research Centres and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Cell Therapy Market

The global surge in personalized medicine is significantly enhancing the adoption of innovative cell therapies, which are pivotal in addressing individual patient characteristics. By tailoring treatments to each person's unique genetic and molecular profile, these therapies improve efficacy and minimize adverse reactions. For instance, CAR T-cell therapy customizes a patient's immune cells to target specific cancer cells, leading to higher remission rates. This precision reduces the likelihood of treatment rejection and enhances overall patient outcomes. As personalized medicine continues to evolve, the integration of advanced cell therapies is expected to play a crucial role in developing more effective and safer treatments.

Restraints in the Cell Therapy Market

The risk of immune rejection significantly hampers the growth potential of the cell therapy market, particularly affecting the adoption of allogeneic treatments. In these therapies, donor cells are introduced into patients, but the recipient's immune system may recognize these cells as foreign, leading to their elimination. This immune response not only diminishes the therapeutic efficacy but also poses challenges in developing universally compatible cell therapies. Consequently, addressing immune rejection is crucial for advancing the widespread application of allogeneic cell therapies.

Market Trends of the Cell Therapy Market

The global incidence of cancer has risen substantially, intensifying the demand for innovative treatments. Chimeric Antigen Receptor T-cell (CAR-T) therapy, an emerging form of immunotherapy, has shown promise in targeting specific cancer cells by reprogramming a patient's own T-cells. This personalized approach enhances treatment efficacy and reduces the likelihood of adverse effects. The CAR-T cell therapy market is projected to grow significantly, with estimates suggesting a rise from USD 7.31 billion in 2024 to USD 188.84 billion by 2034, reflecting a compound annual growth rate (CAGR) of 36.8% during 2025-2034. Pharmaceutical companies are increasingly investing in CAR-T therapies to expand their portfolios and meet the growing demand for effective cancer treatments. For instance, AstraZeneca's recent acquisition of EsoBiotec, a biotech firm specializing in in-vivo CAR-T cell therapies, underscores the industry's commitment to advancing cell therapy innovations. By aligning with this trend, companies can enhance their market presence and contribute to the development of novel cancer therapies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Cell Therapy Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Somatic Cell Technology
• Cell Immortalization Technology
• Viral Vector Technology
• Genome Editing Technology
• Cell Plasticity Technology
• Three-Dimensional Technology

Global Cell Therapy Market Size by Type & CAGR (2025-2032)

• Market Overview
• Autologous
• Allogeneic

Global Cell Therapy Market Size by Cell Type & CAGR (2025-2032)

• Market Overview
• Stem Cell
• Non-Stem Cell

Global Cell Therapy Market Size by Cell Source & CAGR (2025-2032)

• Market Overview
• iPSCs
• Bone Marrow
• Umbilical Cord Blood-Derived Cells
• Adipose Tissues
• Neural Stem Cell

Global Cell Therapy Market Size by Application & CAGR (2025-2032)

• Market Overview
• Musculoskeletal
• Cardiovascular
• Gastrointestinal
• Neurological
• Oncology
• Dermatology
• Wounds and Injuries
• Ocular
• Others

Global Cell Therapy Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals and Clinics
• Regenerative Medicine Centres
• Diagnostic and Research Centres
• Others

Global Cell Therapy Market Size & CAGR (2025-2032)

• North America (Technology, Type, Cell Type, Cell Source, Application, End-User)
  • US
  • Canada
• Europe (Technology, Type, Cell Type, Cell Source, Application, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Technology, Type, Cell Type, Cell Source, Application, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Technology, Type, Cell Type, Cell Source, Application, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Technology, Type, Cell Type, Cell Source, Application, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bluebird Bio, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mesoblast Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CRISPR Therapeutics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adaptimmune Therapeutics plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fate Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orchard Therapeutics plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gamida Cell Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allogene Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Capricor Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vericel Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mustang Bio, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Atara Biotherapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations